Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.59 |
| ▸ | CDK9 | P50750 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 5/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 5/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264774 | 0.93 | IRAK4 (0.57) | IRAK4MAP3K7CDK9CDK2CCNT1 | |
| SCHEMBL271149 | 0.83 | EGFR (0.58) | IRAK4CDK2EGFRBTKNTRK1 | |
| SCHEMBL271021 | 0.83 | SYK (0.68) | IRAK4CDK2EGFRBTKNTRK1 | |
| SCHEMBL17915908 | 0.82 | IRAK4 (0.63) | IRAK4MAP3K7CDK9CDK2CCNT1 | |
| SCHEMBL270995 | 0.79 | BRD4 (0.61) | IRAK4MAP3K7CDK9CDK2PDGFRB | |
| SCHEMBL270521 | 0.79 | IRAK4 (0.60) | IRAK4MAP3K7CDK9CDK2CCNT1 | |
| SCHEMBL301773 | 0.79 | MAP3K7 (0.60) | IRAK4MAP3K7CDK9CDK2CCNT1 | |
| SCHEMBL266089 | 0.79 | BRD4 (0.60) | EGFRBTKBRD4JAK2HDAC1 | |
| SCHEMBL12279582 | 0.79 | IRAK4 (0.58) | IRAK4MAP3K7CDK9CDK2CCNT1 | |
| SCHEMBL271520 | 0.79 | AURKA (0.51) | CDK2EGFRBTKBRD4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | IRAK4 157/4885MAP3K7 35/4885CDK9 51/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | IRAK4 368/4885MAP3K7 1110/4885CDK9 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.